Healthtech Startup ErlySign Secures Rs 16 Crore in Pre-Series A Funding
The healthtech startup ErlySign has successfully raised Rs 16 crore (approximately $1.8 million) in its pre-Series A funding round, led by investor Ashish Kacholia. The newly acquired funds will be allocated towards clinical trials, obtaining approvals from the Central Drugs Standard Control Organisation (CDSCO), and advancing the market launch of ErlySign’s oral cancer detection kit.
About ErlySign
Founded in 2019 by Shubhendra Singh Thakur and Deovrat Begde, ErlySign is dedicated to creating innovative solutions for the early detection of oral cancer. The company claims to have developed India’s first salivary biomarker-based test, which can detect pre-cancerous conditions much earlier than visible symptoms appear.
Future Developments
Looking to the future, ErlySign aims to implement CRISPR miRNA-based testing technology, enabling the identification of multiple cancer types using a single saliva sample. This advanced testing process is expected to yield results within a rapid timeframe of 15 to 20 minutes.